Celldex Therapeutics

Celldex Therapeutics makes new medicines to help people suffering from severe skin allergies and chronic swelling. These treatments work by controlling specific immune system cells that cause constant itching and hives. The company focuses on patients whose symptoms are not helped by standard allergy pills.

Fighting Hives and Inflammation

• Barzolvolimab: Monoclonal antibody that blocks the KIT receptor to reduce the number of mast cells; currently in late-stage testing for chronic hives and skin conditions.
• CDX-622: Bispecific treatment designed to block two different pathways that cause lung and skin inflammation; currently undergoing early human safety tests.
• Antibody Platform: Discovery programs using specialized technology to create antibodies that can either activate or block immune responses to treat various diseases.

Partnerships and Clinical Progress

• Completed a 2022 settlement agreement with Shareholder Representative Services LLC to resolve payment disputes from the 2016 Kolltan Pharmaceuticals, Inc. acquisition.
• Maintains research and licensing collaborations with Amgen Inc. and Yale University to develop new drug candidates.
• Finished patient enrollment for large-scale clinical trials in chronic hives during February 2026.
• Generated approximately $323.9 million in net proceeds through a public stock offering completed in April 2026.

Specializing in Mast Cell Science

Celldex focuses its research on mast cells, which are the primary triggers for many allergic and inflammatory reactions in the human body. By targeting the KIT receptor, the company aims to deplete these cells directly rather than just blocking the chemicals they release.

Tracking the Numbers

• Total revenue fell to $15,000 in Q1 2026, down 97.8% from $695,000 in Q1 2025.
• Net loss deepened to $78.7 million in Q1 2026, a 46.3% increase compared to the $53.8 million loss in Q1 2025.
• Research and development expenses rose to $73 million in Q1 2026, up from $52.6 million in the same period the previous year.
• Free cash flow worsened by 23% to a loss of $67.2 million for the three months ended March 31, 2026.
• The company reported $451.5 million in cash, cash equivalents, and marketable securities as of March 31, 2026.

Bottom Line

Celldex has transitioned into a specialized developer of treatments for chronic inflammatory and allergic diseases. Its future path depends on the successful completion of late-stage clinical trials for its lead drug candidate.